The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2024 | Promising combinations being explored for IDH1 & IDH2-mutated AML
Eytan Stein, MD, Memorial Sloan Kettering Cancer Center, New York, NY, discusses potential combination therapies for treating IDH1 and IDH2-mutated acute myeloid leukemia (AML). He emphasizes the potential benefits of pairing IDH inhibitors with intensive chemotherapy, menin inhibitors, or FLT3 inhibitors. This interview took place at the 29th Congress of the European Hematology Association (EHA) in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
